Dr. Robert M. Califf, MD, is the FDA's commissioner of food and drugs. As the top official of the Food and Drug Administration (FDA), Dr. Califf is committed to strengthening programs and policies that enable the agency to carry out its mission to protect and promote the public health.
“I am honored to have the opportunity to serve as the Commissioner of the U.S. Food and Drug Administration. A successful FDA is a critical factor for better public health in this changing world. I look forward to further building the FDA’s excellent workforce, while relentlessly focusing on the completion of priority projects and continuing to develop the science base that we need to give consumers and patients even more confidence that their food is safe and their medical products are safe and effective.” Dr. Califf
FDA Voice Blog Posts
Academic Medical Centers and FDA – Working Together for the Future 21st Century Cures Act: Making Progress on Shared Goals for Patients
- FDA's Opioids Action Plan: A Midyear Checkup
The Unique Voices of Our Patient Representatives FDA Takes Action against Zika Virus FDA: A Great Place for Scientists on the Frontier of Regulatory Science
- Unveiling the New Nutrition Facts Label
Building Out a National System for Evidence Generation Priorities - Teamwork to Achieve Common Goals Clarifying What We Mean When We Talk About Biomarkers: An NIH/FDA Joint Leadership Council Success Changing course: A new approach to opioid pain medication at FDA 2016: The Year of Diversity in Clinical Trials What We Mean When We Talk About Data The Merging of Medical Products: Enhancing review of therapeutic and diagnostic combination products Why Partnerships are Key to the Science of Patient Input
- FDA’s Patient Preference Initiative: The Need for Evolving Tools and Policies
FDA Announces First-ever Patient Engagement Advisory Committee More Collaboration, Research Needed to Develop Cures
Speech by FDA Commissioner Robert M. Califf to the 2016 Rx Opioid and Drug Abuse Summit Atlanta, Georgia
- A Proactive Response to Prescription Opioid Abuse
N Engl J Med. 2016 Feb 4 ; doi: 10.1056/NEJM sr1601307.
- Engaging Patients across the Full Spectrum of Medical Product Development
JAMA. 2015 Nov 19:1-3. doi: 10.1001/jama.2015.15818.
- FDA as a Catalyst for Translation
Sci Transl Med. 2015 Jul 15;7(296):296ed9. doi: 10.1126/scitranslmed.aab2404.
- Sunscreen and the FDA
N Engl J Med. 2015 Jul 9;373(2):197. doi: 10.1056/NEJMc1507737.